Teachers Retirement System of The State of Kentucky increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 100.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 18,004 shares of the biopharmaceutical company’s stock after purchasing an additional 9,013 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Regeneron Pharmaceuticals were worth $8,698,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Alliancebernstein L.P. increased its position in shares of Regeneron Pharmaceuticals by 13.4% during the fourth quarter. Alliancebernstein L.P. now owns 1,763,344 shares of the biopharmaceutical company’s stock worth $851,889,000 after purchasing an additional 208,936 shares in the last quarter. Norges Bank acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $506,839,000. Sands Capital Management LLC boosted its stake in Regeneron Pharmaceuticals by 2.0% during the third quarter. Sands Capital Management LLC now owns 856,472 shares of the biopharmaceutical company’s stock worth $479,436,000 after buying an additional 17,057 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Regeneron Pharmaceuticals by 1.0% during the fourth quarter. Bank of New York Mellon Corp now owns 828,264 shares of the biopharmaceutical company’s stock worth $400,141,000 after buying an additional 8,138 shares during the last quarter. Finally, UBS Asset Management Americas Inc. boosted its stake in Regeneron Pharmaceuticals by 8.7% during the fourth quarter. UBS Asset Management Americas Inc. now owns 643,442 shares of the biopharmaceutical company’s stock worth $310,853,000 after buying an additional 51,243 shares during the last quarter. Hedge funds and other institutional investors own 85.00% of the company’s stock.
A number of equities analysts have weighed in on REGN shares. Credit Suisse Group boosted their price objective on Regeneron Pharmaceuticals from $753.00 to $760.00 and gave the stock an “outperform” rating in a research note on Monday, March 1st. FIX raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and lowered their price objective for the stock from $635.00 to $575.00 in a research note on Friday, January 8th. Benchmark raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $590.00 price target on the stock in a research note on Wednesday, January 13th. Morgan Stanley decreased their price target on Regeneron Pharmaceuticals from $553.00 to $525.00 and set an “equal weight” rating on the stock in a research note on Monday, February 8th. Finally, SVB Leerink upped their price target on Regeneron Pharmaceuticals from $655.00 to $657.00 and gave the company an “outperform” rating in a research note on Thursday, April 1st. Five analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $637.21.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, February 4th. The biopharmaceutical company reported $9.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.11 by $2.42. The firm had revenue of $2.42 billion during the quarter, compared to analysts’ expectations of $2.40 billion. Regeneron Pharmaceuticals had a return on equity of 28.97% and a net margin of 38.28%. The business’s revenue was up 11.7% on a year-over-year basis. During the same period in the prior year, the firm earned $7.50 EPS. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 27.23 earnings per share for the current fiscal year.
In related news, Director Michael S. Brown sold 2,480 shares of the company’s stock in a transaction dated Monday, January 25th. The stock was sold at an average price of $554.32, for a total value of $1,374,713.60. Following the completion of the sale, the director now directly owns 3,371 shares of the company’s stock, valued at approximately $1,868,612.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 11.84% of the stock is owned by corporate insiders.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Further Reading: CAC 40 Index
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.